Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Medicine and Dentistry
Breast Cancer
100%
Tumor
81%
Pheochromocytoma
76%
Oncology
75%
Paraganglioma
71%
Malignant Neoplasm
60%
Diseases
57%
Chemotherapy
53%
Neoplasm
45%
Metastatic Breast Cancer
44%
Genetics
42%
Cancer
38%
Hormone Therapy
38%
Clinical Trial
37%
Overall Survival
37%
Arm
33%
Immunotherapy
28%
Triple Negative Breast Cancer
26%
Non-Hodgkin Lymphoma
26%
Progression Free Survival
26%
Diffuse Large B-Cell Lymphoma
25%
Prostate Cancer
24%
Myelofibrosis
24%
Receptor
23%
Interleukin 2
23%
Ovarian Cancer
23%
Estrogen Receptor
23%
Drug Megadose
22%
Targeted Therapy
20%
Clear Cell Renal Cell Carcinoma
19%
Adverse Event
19%
Lymphocyte
19%
COVID-19
18%
Lymphokine Activated Killer Cell
18%
Pembrolizumab
18%
Elacestrant
18%
Hazard Ratio
18%
Recurrent Disease
18%
Melanoma
18%
Lung
17%
Leukemia
16%
Cancer Therapy
16%
Succinate Dehydrogenase
16%
Myeloproliferative Neoplasm
16%
Hodgkin's Lymphoma
16%
Oral
16%
Acute Lymphoblastic Leukemia
15%
Polycythemia vera
15%
Colorectal Carcinoma
15%
Hormone Receptor
15%
Germline Mutation
15%
Placebo
15%
Cohort Analysis
15%
Cancer Survival
15%
Phase II Trials
14%
T Cell
14%
In Vitro
14%
Hepatocellular Carcinoma
14%
SDHB
14%
Ruxolitinib
13%
Brain Metastasis
13%
Acute Myeloid Leukemia
13%
B Cell
13%
Disease Free Survival
12%
B-Cell Lymphoma
12%
Biological Marker
11%
Solid Malignant Neoplasm
11%
Neuroendocrine Tumor
11%
Pancreas Adenocarcinoma
11%
Programmed Death 1 Ligand 1
11%
Systematic Review
11%
Cell-Free DNA
11%
Veterans Health
11%
Phosphotransferase
11%
Doxorubicin
11%
Spontaneous Remission
11%
Immune Checkpoint Inhibitor
10%
Vincristine
10%
Adjuvant Therapy
10%
CHOP
10%
Next Generation Sequencing
10%
Genetic Screening
10%
Prognostic Factor
10%
Pancreas Cancer
10%
Antineoplastic Activity
10%
Carcinogenesis
9%
Biopsy Technique
9%
Penetrance
9%
Personalized Medicine
9%
Bladder Cancer
9%
Cyclophosphamide
9%
BRCA1
9%
Hydroxyurea
9%
CDK4/6 Inhibitor
9%
SDHD
9%
Gamma Urogastrone
8%
Everolimus
8%
Programmed Death-Ligand 1
8%
Health Care Cost
8%
Lymphoid Cell
8%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
69%
Neoplasm
64%
Diseases
57%
Breast Cancer
53%
Adverse Event
52%
Pharmacokinetics
51%
Chemotherapy Regimens
46%
Malignant Neoplasm
43%
Overall Survival
40%
Progression Free Survival
38%
Metastatic Breast Cancer
32%
Clinical Trial
32%
Nonhodgkin Lymphoma
30%
Pembrolizumab
30%
Glioblastoma
25%
Cyclophosphamide
24%
Chronic Lymphatic Leukemia
23%
Remission
23%
Doxorubicin
22%
Antitumor Activity
22%
Ovary Cancer
21%
Mitoxantrone
21%
Placebo
20%
Myelofibrosis
20%
Prostate Cancer
19%
Estrogen Receptor
19%
Vincristine
18%
Melanoma
17%
Monotherapy
17%
Hodgkin Disease
17%
Liver Cell Carcinoma
17%
Triple Negative Breast Cancer
17%
Ruxolitinib
17%
Maximum Tolerated Dose
16%
Tolerability
16%
Endocrine Therapy
15%
Receptor
15%
Immunotherapy
15%
Alisertib
15%
Phase II Trials
14%
Pharmacodynamics
13%
Histone Deacetylase Inhibitor
13%
Docetaxel
12%
Polycythemia vera
12%
Phase I Trials
12%
Metastatic Colorectal Cancer
12%
Carcinogenesis
11%
Bevacizumab
11%
Liver Dysfunction
11%
Prednisone
11%
Phosphotransferase Inhibitor
11%
Cytarabine
11%
Hormone Receptor
11%
Biological Marker
11%
Methotrexate
11%
Lurbinectedin
11%
Rhenium 186
11%
Pheochromocytoma
11%
Paraganglioma
11%
Eribulin
11%
Estrogen Receptor Beta
11%
Hydroxychloroquine
11%
Vorinostat
11%
Tumor Growth
11%
Combination Therapy
10%
Anticarcinogen
10%
Protein Tyrosine Kinase Inhibitor
10%
Colorectal Carcinoma
10%
Leukemia
10%
Pancreas Adenocarcinoma
10%
Renal Cell Carcinoma
9%
Epidermal Growth Factor Receptor
9%
Drug Development
9%
Ibrutinib
9%
Small Cell Lung Cancer
8%
Hydroxycarbamide
8%
Flow Cytometry
8%
Carmustine
8%
Acute Myeloid Leukemia
8%
Interleukin 2
8%
Hematologic Malignancy
8%
Advanced Cancer
8%
Dexamethasone
8%
Pancreas Cancer
8%
Multiple Myeloma
7%
Paclitaxel
7%
Diarrhea
7%
Androgen
7%
Mild Hepatic Impairment
7%
Cabazitaxel
7%
Sonidegib
7%
Hedgehog
7%
Castration Resistant Prostate Cancer
7%
Lymphokine
7%
Acute Lymphoblastic Leukemia
7%
Interferon
7%
Spartalizumab
7%
Temozolomide
7%
Bisantrene
7%
Tucatinib
7%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
42%
BRCA1
39%
Genomics
36%
Carcinogenesis
35%
Homologous Recombination
34%
Germ Cell
33%
Germline Mutation
33%
Germline
33%
DNA Repair
32%
Transcription
29%
Gene Expression
27%
Genetics
23%
Deficiency
22%
Estrogen Receptor
20%
DNA Damage
18%
Tumor Suppressor Gene
18%
Genome Instability
18%
Genetic Divergence
17%
Susceptibility Gene
17%
B Cell
17%
Neural Crest
16%
Tumor Suppressor Protein
16%
Promoter Region
16%
DNA Damage Response
15%
Macrophage
15%
SDHB
15%
Fumarate Reductase
15%
RNA
14%
Genetic Screening
13%
Ubiquitination
13%
Somatic Mutation
13%
Wild Type
13%
Isoform
13%
Gene Mutation
13%
Small Molecule
13%
Succinate Dehydrogenase
13%
Transmembrane Protein
12%
Enzyme
12%
RAD51
12%
Endonuclease
12%
Programmed Cell Death
12%
Penetrance
12%
Synthetic Lethality
11%
Overall Survival
11%
Synapsin I
11%
Histone Deacetylase
11%
Lectin
11%
Estrogen Receptor Beta
11%
T Cell
10%
Next Generation Sequencing
10%
Drug Resistance
10%
Allele
10%
Cell Cycle
10%
Myeloid
10%
Ferroportin
10%
Flow Cytometry
9%
Retinoblastoma
9%
Progression Free Survival
9%
Chromosome Instability
9%
Tumor Volume
9%
Homeostasis
9%
Demethylase
9%
Exome Sequencing
9%
Tumor Progression
9%
Nuclease
9%
Clinical Trial
8%
Gene Expression Profiling
8%
Oxidoreductase
8%
Targeted Therapy
8%
Phosphotransferase
8%
Kinase
8%
Immune Checkpoints
8%
Cancer Immunotherapy
8%
CD44
8%
P53
8%
Tartrate-Resistant Acid Phosphatase
8%
Hypoxia-Inducible Factors
7%
Catecholamine
7%
Von Hippel-Lindau Disease
7%
Exon
7%
Cell Proliferation
7%
Polygenic Score
7%
Non-Homologous End Joining
7%
Nanoliposome
7%
Microsatellite
7%
Hormone Receptor
7%
Response Element
7%
Autophagy
7%
R-Loop
7%
Polyploid
7%
Mesenchymal-Epithelial Transition
7%
Binding Protein
7%
CD8
7%
Chromosome
6%
Mammalian Target of Rapamycin
6%
Genotyping
6%
DNA Flanking Region
6%
DNA Binding
6%
Cancer Genetics
6%
Transcriptomics
6%